Cancer Epidemiology, Biomarkers & Prevention

Gastric Cancer is Related to Early *Helicobacter pylori* Infection in a High-Prevalence Country

Catterina Ferreccio, Antonio Rollán, Paul R. Harris, et al.

Updated version	Access the most recent version of this article at: http://cebp.aacrjournals.org/content/16/4/662

Cited Articles	This article cites by 30 articles, 6 of which you can access for free at: http://cebp.aacrjournals.org/content/16/4/662.full.html#ref-list-1
Citing articles	This article has been cited by 1 HighWire-hosted articles. Access the articles at: http://cebp.aacrjournals.org/content/16/4/662.full.html#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.

Gastric Cancer is Related to Early *Helicobacter pylori* Infection in a High-Prevalence Country

Catterina Ferreccio,[1] Antonio Rollán,[1] Paul R. Harris,[1] Carolina Serrano,[1] Alessandra Gederlini,[1] Paula Margozzini,[1] Claudia Gonzalez,[3] Ximena Aguilera,[3] Alejandro Venegas,[2] and Alejandro Jara[1,4]

[1]Facultad de Medicina and [2]Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, and [3]Departamento de Epidemiología, Ministerio de Salud de Chile, Santiago, Chile; and [4]Biostatistical Centre, Catholic University of Leuven, Leuven, Flanders, Belgium

Abstract

Background and Aims: **Chile ranks fifth in the world among countries with the highest incidence of gastric cancer. The aim was to quantify the association between *Helicobacter pylori* infection and gastric cancer mortality at the county of residence.** Methods: **A cross-sectional household survey, a probability sample of the Chilean adult population, provided 2,615 participants in whom serum *H. pylori* IgG antibodies were measured (ELISA). The spatial pattern of 48,367 deaths due to gastric cancer which occurred from 1985 to 2002 was analyzed using a hierarchical Poisson regression model; 333 counties were categorized as low, medium, and high gastric cancer mortality with median gastric cancer death rates of 11.4, 19.1, and 26.0 per 100,000 inhabitants, respectively. The association between *H. pylori* positivity and gastric cancer mortality in the county of residence was assessed by multivariate Poisson regression for complex samples.**

Results: ***H. pylori* prevalence was 73.0% [95% confidence intervals (CI), 70.0-76.0], higher in men [prevalence rate ratio (PRR), 1.1 (95% CI, 1.01-1.20)], peaked at ages 45 to 64, and dropped after age 65. It was higher among residents in counties with high gastric cancer mortality (79.7%; 95% CI, 76.4-82.6) compared to counties with low gastric cancer mortality (62.3%; 95% CI, 53.8-70.2; corresponding PRR, 1.3; 95% CI, 1.1-1.5); under age 24, *H. pylori* infection was 79.7% (95% CI, 72.2-85.6) versus 39.8% (95% CI, 19.6-64.2) among residents in counties with high and low gastric cancer mortalities, respectively (PRR, 2.0; 95% CI, 1.1-3.7).**
Conclusions: **The high prevalence of *H. pylori* at younger ages was associated with high gastric cancer mortality in the base population.** (Cancer Epidemiol Biomarkers Prev 2007;16(4):662–7)

Introduction

There is abundant evidence of the association between chronic infection with *Helicobacter pylori* and the development of gastric cancer (1-5). Some population-based studies showed that high levels of *H. pylori* infection were not accompanied by high gastric cancer mortality, the so-called African (6-8) and Asian enigmas (9). The wide variation in the risk of gastric cancer mortality in Chile, with a relatively homogeneous population, would permit us to assess the ecological association of gastric cancer and *H. pylori*. The only population-based prevalence study of *H. pylori* in Chile did not explore its association with gastric cancer (10). Historically, Chile has been among the countries with the highest risk of gastric cancer in the world (11). Even though Chile has experienced sustained socioeconomic growth since the 1980s, the gastric cancer rate has decreased only slowly. From 1985 to 2002, mortality from gastric cancer was 19.2 per 100,000 inhabitants with wide variation among counties, ranging from 5.5 (Vitacura) to 48.2 (Molina) per 100,000 inhabitants (12). We hypothesized that this difference in gastric cancer mortality could be explained by differences in the background prevalence of *H. pylori* infection, a potentially controllable risk factor. If a significant excess of *H. pylori*

infection were shown, an avenue for a public health intervention would open. The first national health survey in Chile, covering a representative sample of the population older than 17 years, made it possible to explore the epidemiology of *H. pylori* infection and its relation with the geographic distribution of gastric cancer (13). Accordingly, the main objective of the present study was to quantify the association between *H. pylori* infection and gastric cancer mortality at the county of residence.

Materials and Methods

Study Population. The 2003 National Health Survey was a national cross-sectional household survey of 3,619 people based on a multistage stratified random sample of the Chilean population over 17 years of age. Only one participant was selected per household, using the Kish method to choose the responding individual (14). Participants completed several specific health questionnaires (history of diabetes, hypertension, peptic ulcer, gastroesophageal reflux, and smoking), physical examinations (blood pressure and anthropometry), and laboratory analyses (fasting glucose, lipid profile, hepatitis A, B, C, and hemoglobin). Available sera from participants were used for measuring antibodies to anti−*H. pylori*. Blood samples were centrifuged and frozen at −30°C until they were transported to the central laboratory at the Pontificia Universidad Católica de Chile, where they were kept at −80°C until processing. Sera for 2,615 subjects, corresponding to 72.2% of the target sample, were available for analysis. Participants were similar to nonparticipants with regard to age (<45 years old, 62.9% and 60%, respectively), sex (men, 47.9% and 51.6%, respectively), area of residence (residing in rural areas, 14.4% and 11.4%, respectively), and

socioeconomic status (<8 years of schooling, 25.1% and 25.5%, respectively). None of the differences reached statistical significance.

Determination of IgG Anti-*H. pylori*. Serum samples were analyzed with a commercial immunoassay for the detection of IgG antibodies to *H. pylori* (Bioelisa Helicobacter, Biokit SA, Barcelona, Spain). Briefly, serum samples were diluted (1:200) and 100 µL aliquots were transferred to each well of a plate coated with inactivated *H. pylori* antigens. Plates were then incubated at 37°C for 45 min and washed. Next, 100 µL of the conjugate (horseradish peroxidase-labeled rabbit antibodies to human IgG) was added to each well. The plates were washed again under the previous conditions and 100 µL of substrate solution with tetramethylbenzidine was added to each well. After 25 min of incubation at room temperature, the reaction was stopped with 10 µL of H_2SO_4 1 N. Finally, the color developed was measured spectrophotometrically at 450 nm in the next 30 min. The cutoff values were based on the standard value of the test calibrators, according to the instructions of the manufacturer, and expressed as arbitrary units per milliliter. In a preliminary study, we evaluated immune response to *H. pylori* through the measurement of specific antibodies directed against a whole cell preparation of *H. pylori* with a noncommercial immunoassay (15). Serum positivity on that study was defined on the basis of cutoff values established by the mean + 3 SD of a normal population from the United States. In a recent study, we compared the noncommercial immunoassay with the commercial assay used in the current study and determined a sensitivity of 90% and a specificity of 50% for the adult group (16). Because variation in sensitivity and specificity according to age has been previously reported, we further extended our analysis by including an older population and the best cutoff values were chosen based on receiver operator curves, with a cutoff value of 72.79 arbitrary units/mL for IgG, reaching a sensitivity and specificity of 87.5% and 62%, respectively. In this evaluation, the gold standard for the ELISA was the presence of *H. pylori* in the stomach as determined by histology.

Statistical Analysis. The adjusted prevalence rates of *H. pylori* were calculated using the sampling weights from the two-stage sampling design and adjusted for poststratifica-tion population totals using the 2003 Chilean population. In view of the complex sample design, the SE and 95% confidence intervals (CI) were calculated with a Taylor linear approxima-tion method using SAS version 8 (17). For international comparison purposes, a direct standardization was done to estimate the overall *H. pylori* prevalence, by considering the age and gender world population structure as proposed by Doll and Cook (18).

Gastric Cancer Mortality Estimation. Computerized infor-mation about deaths from gastric cancer between 1985 and 2002 (48,367 deaths), registered separately for the 333 Chilean counties, was obtained from the Ministry of Health (12). Estimates of the population (~15 million inhabitants), stratified by age, sex, and county were obtained from the National Institute of Statistics (19). Relative risk of gastric cancer at the county level was estimated by an internal age/ sex standardization of the gastric cancer cumulative rate using the 1985 to 2002 national average rates as reference. The spatial pattern of relative risk was analyzed using a Bayesian hierarchical Poisson regression model. In addition to classical Standardized Mortality Ratio (SMR) estimates, two statistical models differing in the form of the variability of relative risk were adjusted. Model 1 assumed a nonspatial pattern (unstructured variability), whereas model 2 used a combination of unstructured variability and spatial depen-dence (structured variability). This spatial variability was taken into account by considering an intrinsic conditional


Figure 1. Spatial distribution of the risk of gastric cancer mortality in 333 Chilean counties (1985-2002).

autoregressive prior distribution (20). Model 2 can be represented by:

$$O_i \sim \text{Poisson } (\mu_i)$$
$$\log \mu_i = \log E_i + \alpha_0 + b_i + h_i,$$

where, α_0 is the intercept that represents the log of the baseline risk of gastric cancer throughout the study area, b_i is the random area-specific effect in the log of relative risk explained by the neighbors of the i*th* county, and h_i is the area-specific random effect not explained by neighbors of the i*th* county. Posterior inference was done by using Markov chain Monte Carlo techniques and the WinBUGS program (21). Convergences were evaluated based on standard criteria using the BOA program (22). Comparison and selection of models were based on the deviance information criterion (23). The

structured model (model 2) was the best model for this data. The estimates of relative risk obtained with model 2 were more stable than the classical SMR. The model confirmed a substantial geographic variation from north to south, and statistically significant differences among counties (see Fig. 1). Based on the modeled relative risk, counties were categorized in tertiles of low, medium, and high gastric cancer mortality with median gastric cancer death rates of 11.4, 19.1, and 26.0 per 100,000 inhabitants, respectively.

Multivariate Analysis. Univariate analyses of relative risk of *H. pylori* infection were calculated using Poisson regression with robust estimates of the variance (24). The main explicatory variable analyzed was residence in a county with high gastric cancer mortality; we also explored the association of *H. pylori* and the 2003 poverty level in the county of residence, i.e., the proportion of the population living below the poverty line (percentage of individuals whose income was insufficient to buy two basic food baskets; ref. 25). Both were county-level variables. Individual-based variables studied were sex, age, educational level (high, medium, and low as a proxy for socioeconomic status), zone of residence at the time of the survey (urban county, >2,000 inhabitants, and rural county, <2,000 inhabitants), tobacco smoking, and antibodies to anti–hepatitis A (proxy for enteric contamination). Variables statistically significant in the univariable analysis were later included in multivariate models to estimate prevalence rate ratios (PRR)—Poisson regression model for complex samples using SPSS version 13. Only those variables that remained significant were left in the final model. The significance level for each test was set to α = 5%.

Results

H. pylori prevalence in adults (>17 years old) was 73.0% (95% CI, 70.0-76.0%); 73.4% adjusted for the world population (18). *H. pylori* infection was significantly higher in men, peaked from ages 45 to 64, and dropped among study participants ages 65 and older. It was also higher among people of low socioeconomic status and those with hepatitis A antibodies (Table 1). The occurrence of *H. pylori* did not differ according to reports of frequent regurgitation or pyrosis (reported by 25.6%), or by history of medical diagnoses of peptic ulcer (reported by 4.7%), or smoking (Table 1). *H. pylori* prevalence was higher among people residing in counties in the high or medium tertiles of poverty versus those residing in counties in the lowest tertile of poverty (75.9%, 76.7%, and 66.3%, respectively; Table 1).

Mean IgG levels (in arbitrary units) were similar among residents of counties with high, medium, and low gastric cancer mortalities: 188.6 (95% CI, 171.8-205.5), 192.0 (95% CI, 177.7-206.4), and 166.0 (95% CI, 149.6-182.4), respectively. Although among 17- to 24-year-olds, IgG levels were significantly higher for residents in counties with high versus low gastric cancer incidences: 182.6 (95% CI, 138.6-226.6) and 92.3 (95% CI, 62.8-121.8), respectively.

H. pylori infection presented a significant and positive association with the gastric cancer mortality of the residence area, as indicated by χ^2 test for trend (Table 2). *H. pylori* prevalence was higher for men and women residing in areas of high cancer incidence [men from areas of high (81.9%) versus low gastric cancer incidence (72.7%); P = 0.04; women from high (77.4%) versus low gastric cancer incidence (64.3%); P = 0.01]. Among the 17- to 24-year-olds residing in counties with a high incidence of gastric cancer, study participants presented a level of *H. pylori* infection twice as high as those from counties with a low incidence of gastric cancer (Table 2). By age 17, 75% of residents from counties with a high incidence of gastric cancer had serologic evidence of *H. pylori* infection, whereas people from counties with a low incidence of gastric cancer reached that level of infection only after 35 years of age (Fig. 2).

H. pylori infection declined at older ages in all counties, but declined earlier among counties with a high versus low incidence of gastric cancer (declining point started at 38 and 49 years old, respectively).

The multivariate Poisson regression analysis indicated a significant effect of gastric cancer mortality, age, gastric cancer mortality × age interaction, and gender on the degree of *H. pylori* infection. The corresponding score statistics (*P*) were 13.95 (0.001), 16.19 (0.001), 16.90 (0.010), and 6.48 (0.011), respectively. For educational level, the score statistic (*P*) was 5.02 (0.081), suggesting the absence of differences in the degree of *H. pylori* infection across socioeconomic levels, after controlling for gastric cancer mortality, age, and gender (Table 3). Poverty level in the county of residence was not significant in the multivariate analysis. The score statistic (*P*) was 2.06 (0.36) and, therefore, it was not included in the final model. The PRR's, resulting from the multivariate Poisson analysis, are shown in Table 3. These results confirm the

Table 1. Prevalence of *H. pylori* by age, sex, and selected characteristics in a sample of 2,615 people (Chile 2003)

Characteristic	*H. pylori*– positive (*n* = 1,950)	Positivity, % (95% CI)*	*H. pylori*⁺/ *H. pylori*⁻, PRR[†] (95% CI)
Sex			
Female	1,042	69.7 (65.3-73.8)	1.0
Male	908	76.8 (72.3-80.8)	1.1 (1.01-1.20)
Age (χ^2 for trend, 8.2; P = 0.004)			
17-24	217	62.0 (53.5-69.9)	1.0
25-44	639	76.8 (72.0-80.9)	1.24 (1.06-1.44)
45-64	654	78.1 (72.5-82.8)	1.26 (1.07-1.47)
65 and older	440	67.1 (61.6-72.2)	1.08 (0.92-1.27)
Educational level[‡] (χ^2 for trend, 15.5; P < 0.001)			
High	238	65.2 (56.8-72.8)	1.0
Medium	947	74.3 (69.9-78.2)	1.14 (0.99-1.31)
Low	765	76.3 (71.0-80.9)	1.17 (1.01-1.34)
Zone			
Urban	1,568	72.3 (68.9-75.5)	1.0
Rural	382	77.9 (71.0-83.6)	1.08 (0.98-1.18)
Hepatitis A			
Negative	88	59.0 (48.2-69.1)	1.0
Positive	635	74.5 (68.9-79.4)	1.26 (1.04-1.53)
Obesity			
No	1,404	71.5 (67.6-75.1)	1.0
Yes	524	78.5 (73.6-82.7)	1.15 (1.04-1.27)
Gastroesophageal reflux or pyrosis			
No	1,421	73.2 (69.4-76.7)	1.0
Yes	500	72.8 (67.7-77.4)	0.99 (0.91-1.09)
Irritable bowel syndrome			
No	1,797	73.5 (70.3-76.5)	1.0
Yes	153	69.5 (58.1-78.9)	0.94 (0.81-1.09)
Hypertension			
No	1,056	71.3 (67.1-75.1)	1.0
Yes	876	76.5 (72.5-80.0)	1.31 (0.98-1.76)
High cholesterol			
No	680	72.1 (66.2-77.3)	1.0
Yes	438	77.2 (72.3-81.5)	1.31 (0.89-1.92)
Smoking			
No	1,261	74.5 (70.7-78.0)	1.0
Yes	645	70.8 (65.9-75.3)	0.83 (0.61. 1.13)
Poverty level in county of residence[§]			
Low	542	66.3 (63.0-69.0)	1.0
Medium	670	76.7 (74.0-80.0)	1.16 (1.09-1.23)
High	649	75.9 (73.0-79.0)	1.15 (1.08-1.22)

NOTE: Prevalence was age/sex-standardized to the 2003 Chilean population.
*SEs and 95% CIs estimated with the Taylor expansion method.
[†] PRR from Poisson regression with robust estimate of the variance error.
[‡] Educational level is a proxy for socioeconomic status.
[§] Percentage of the population living below the poverty level in the county of residence.

Table 2. Prevalence of IgG anti–*H. pylori* among people residing in counties of high, medium, or low mortality of gastric cancer

	Prevalence (%) of *H. pylori*				
	High gastric cancer, *n* = 1,306 (95% CI)*	Medium gastric cancer, *n* = 882 (95% CI)*	Low gastric cancer, *n* = 427 (95% CI)*	Medium gastric cancer/low gastric cancer, PRR[†] (95% CI)*	High gastric cancer/low gastric cancer, PRR[†] (95% CI)*
Age					
17-24	79.7 (72.2-85.6)	49.3 (36.7-62.0)	39.8 (19.6-64.2)	1.2 (0.6-2.4)	2.0 (1.1-3.7)
25-44	82.6 (76.1-87.7)	75.4 (67.3-82.0)	65.4 (52.6-76.3)	1.1 (0.9-1.4)	1.2 (1.0-1.6)
45-64	79.3 (73.4-84.1)	80.3 (72.2-86.5)	70.0 (47.9-85.5)	1.15 (0.9-1.4)	1.1 (0.9-1.4)
≥65	68.1 (61.3-74.2)	64.4 (54.6-73.1)	71.4 (55.6-83.3)	0.9 (0.7-1.1)	0.9 (0.8-1.1)
Total	79.7 (76.4-82.6)	70.7 (65.4-75.5)	62.3 (53.8-70.2)	1.1 (0.9-1.3)	1.3 (1.1-1.5)
χ^2 for trend	54.23; *P* < 0.001				

*SEs and 95% CI estimated with the Taylor expansion method.
[†] PRR, relative risk from Poisson regression with robust estimate of the variance error.

findings described previously for Table 2 and Fig. 2, and suggest that age modifies the association between gastric cancer mortality in county of residence and *H. pylori* infection. Taking the 17- to 24-year-old age group from counties with a low mortality of gastric cancer as reference, the PRR was five times higher among adults ages 45 to 64 years from counties with a medium mortality of gastric cancer and was also five times higher among study participants ages 17 to 64 years from counties with a high mortality of gastric cancer (*P* < 0.005, with Bonferroni correction for multiple comparisons). The ratio was much attenuated and nonsignificant comparing the youngest from counties with low gastric cancer to those >65 years of age from counties with either medium or high gastric cancer.

Discussion

The national prevalence of *H. pylori* infection standardized for the world population for ages 20 to 60 was 74.5%. This high level of *H. pylori* infection may explain why Chile has the highest rate of gastric cancer mortality in the Americas, and is among the top five countries in the world with regard to gastric cancer mortality (11).

This study confirmed, at the ecological level, the association between *H. pylori* and gastric cancer; in the counties with high gastric cancer mortality, *H. pylori* prevalence was significantly higher than in those with low gastric cancer mortality (79.7%

Figure 2. Age prevalence of *H. pylori* infection by gastric cancer mortality in the county of residence (adjusted according to generalized additive model with penalized likelihood maximization).

and 62.3%, respectively). This difference was even higher at younger ages (17-24 years) in which *H. pylori* prevalence was twice as high among people residing in counties of high compared with those residing in counties of low gastric cancer mortality (79.7% and 39.8%, respectively). This result might have been higher had we studied younger subjects (<17 years old). In a previous study, Armijo showed that the only risk factors for gastric cancer in Chile were tobacco use and the duration of residence in zones with a high gastric cancer mortality before turning 25 years old (26). The earlier age at which *H. pylori* infection begins to decline in counties of high gastric cancer mortality may reflect the earlier installation of atrophy and the longer time at risk of developing gastric cancer.

The inconsistencies that have been described in the association between *H. pylori* and gastric cancer at the population level (27, 28) may be explained in part by the lack of accuracy in serologic testing and by variations in study conditions. We did not find a spatial association between gastric cancer and *H. pylori* when analyzed at the level of large conglomerates—the 13 regions of the country—the association was only evident in smaller geographic units, that is, the 333 counties. The use of large populations may explain the lack of association between *H. pylori* and mortality from gastric cancer in Mexico (27). A recent study in Colombia (28) reports an equal infection rate of *H. pylori* in areas of high (Pasto) and low (Tumaco) risk for gastric cancer (59.7% and 58.6%, respectively). This apparent paradox could be explained by racial differences (as stated by the authors, Pasto is predominantly Spanish-Amerindian, whereas Tumaco is predominantly of African-Spanish ancestry) or the environmental differences between the two cities (Pasto is at a high altitude in the Andean mountains and is mostly agricultural, whereas Tumaco is by the Pacific coast). In our study, the population was highly homogeneous, mostly Spanish-Amerindians, we controlled by individual socioeconomic status and by county poverty level, and included participants from counties from all over Chile, and this could have diluted the effect of unmeasured potential confounders.

In Chile, men had a 64% greater gastric cancer mortality than women (29.0 and 10.5 gastric cancer deaths per 10^5 habitants, respectively; ref. 12) but their *H. pylori* prevalence was only 9.2% higher (76.8% and 69.7% for men and women, respectively). Other cofactors may explain men's higher risk: 23% higher smoking rate (48% men and 37% women; ref. 13) and 22% higher abuse of salt in foods (addition of salt to food before tasting was 10.9% and 8.5% for men and women, respectively; ref. 29). The protective role of female hormones has also been proposed (30).

Although *H. pylori* was marginally more frequent among those subjects with anti–hepatitis A antibodies (relative risk, 1.26; see Table 1), the significance disappeared when adjustments were made for the risk of gastric cancer in the county of

Table 3. Multivariate Poisson regression analysis for *H. pylori* infection

Factor (reference category)	Score statistics	P	PRR (95% CI)*	P
Sex				
Female	6.5	0.010		
Male			1.48 (1.09-2.01)	0.011
Education level				
High	5.02	0.081		
Medium			1.45 (0.96-2.17)	0.076
Low			1.75 (1.08-2.83)	0.022
Gastric cancer × age[†]	21.14	0.007		
Low (y)				
17-24				
25-44			2.79 (0.90-8.66)	0.075
45-64			3.58 (0.99-13.02)	0.052
≥65			3.30 (0.95-11.50)	0.061
Medium (y)				
17-24			1.40 (0.43-4.54)	0.575
25-44			4.46 (1.51-13.15)	0.007
45-64			5.47 (1.79-16.70)	0.003[‡]
≥65			2.22 (0.71-6.97)	0.172
High (y)				
17-24			5.67 (1.90-16.92)	0.002[‡]
25-44			6.63 (2.25-19.53)	0.001[‡]
45-64			4.94 (1.67-14.65)	0.004[‡]
≥65			2.57 (0.83-7.92)	0.100

*PRR, relative risk from multivariate Poisson regression with robust estimate of the variance error.

[†] Factor considering the levels of the interaction term of age and gastric cancer risk.

[‡] $P < 0.005$, with Bonferroni correction for multiple comparisons.

residence. Hepatitis A infection was unrelated with gastric cancer mortality in the county of residence. The apparent lack of effect of general environmental improvements (almost 100% of basic sanitation and sewage coverage by 2005) in *H. pylori* prevalence may be explained by the latency in effect due to the chronic condition of *H. pylori* infection or to a different mechanism of transmission of *H. pylori* and hepatitis A. Other authors have previously reported the different epidemiologies between *H. pylori* and hepatitis A (31, 32). The lack of association between *H. pylori* infection and a history of gastric ulcer may reflect the effect of medical treatment because 85% of these people reported that they had been treated. Finally, variations in *H. pylori* strains have been proposed as an explanation for the changes in the effect of *H. pylori* (5). However, we found similar a seroprevalence for Cag A–positive strains in a subsample of 267 subjects residing in counties at high or low risk (66% and 69%, respectively); although the sample size was too small to rule out this possibility.

This is the first national level study of the population distribution of *H. pylori* infection and its relation with the risk of gastric cancer. We developed a spatial model for gastric cancer mortality risk that is more stable than SMR, particularly for very small populations. This baseline model can now be used to explore different causal hypotheses at the population level. The principal limitation is inherent to the hybrid design, which combines conglomerate variables (risk of gastric cancer in the county of residence) with individual variables (participants' antibodies against *H. pylori*). The analysis assigns the risk of county of residence to the individual, which implies some assumptions (homogeneity of risk within the county, permanent residence there, and that other risk factors for gastric cancer were homogeneous within counties).

The model used to estimate the baseline gastric cancer mortality in each county has a spatial smoothing function that takes account of the influence of neighbors. Interregional migration in Chile is among the lowest registered. From 1965 to 2000, annual internal migration was only 0.6% in

comparison with 1.2% in Argentina, 3.1% in the United Kingdom, and 6.6% in the United States (33). Some diseased individuals from regions at high-risk may migrate to the capital city of Santiago to obtain medical care, artificially elevating cancer rates in the Metropolitan area, whereas simultaneously decreasing the rates in areas at risk. Thus, migration would attenuate the risk estimates calculated. Gastric cancer at the national level has been extraordinarily stable in the last 20 years; its death rate per 100,000 population was 19.6 in 1984 and 19.0 in 2004, the lowest was 18.6 in 1985, the highest was 21.2 in 1982. At the county level, the rates may vary randomly from year to year associated with small population size. The model adjusts for the random temporal variations in the observed number of cases. We did not study temporal trends because our interest was to obtain a summary measure of risk for the study period. This summary measure may hide trends in risk in some counties. Regarding the quality of mortality data, almost 100% of the deaths recorded in Chile had a death certificate, and the large majority were completed by physicians (34).

The low specificity of the *H. pylori* ascertainment method may be explained, among other factors, by cross-reactivity with other non–*H. pylori* infections, by lack of detection of *H. pylori* in the biopsies (sample error; refs. 35-38), or by spontaneous eradication. Nevertheless, only a minority of infected individuals could eradicate the infection spontaneously (39), except when the development of gastric mucosal atrophy renders the gastric environment hostile to the bacterium. The misclassification of *H. pylori* status may decrease the association between the exposure and the effect. In conclusion, heterogeneity in *H. pylori* infection may explain the differences in gastric cancer mortality around Chile.

Acknowledgments

References

1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and *Helicobacter pylori*: infection with *Helicobacter pylori*. IARC Monogr Eval Carcinog Risks Hum 1994;61:177–240.
2. Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone marrow-derived cells. Science 2004;306:1568–71.
3. Uemura N, Okamoto S, Yamamoto S, et al. *Helicobacter pylori* infection and the development of gastric cancer. N Engl J Med 2001;345:784–9.
4. Wang TC, Fox JG. *Helicobacter pylori* and gastric cancer: Koch's postulates fulfilled? Gastroenterology 1998;115:780–3.
5. Eslick GD. *Helicobacter pylori* infection causes gastric cancer? A review of the epidemiological, meta-analytic, and experimental evidence. World J Gastroenterol 2006;12:2991–9.
6. Holcombe C. *Helicobacter pylori*: the African enigma. Gut 1992;33:429–31.
7. Lunet N, Barros H. *Helicobacter pylori* infection and gastric cancer: facing the enigmas. Int J Cancer 2003;106:953–60.
8. Tokudome S, Kuriki K, Suzuki S, et al. Re: *Helicobacter pylori* infection and gastric cancer: facing the enigmas. Int J Cancer 2004;112:166–7.
9. Singh K, Ghoshal UC. Causal role of *Helicobacter pylori* infection in gastric cancer: an Asian enigma. World J Gastroenterol 2006;12:1346–51.
10. Hopkins RJ, Vial PA, Ferreccio C, et al. Seroprevalence of *Helicobacter pylori* in Chile: vegetables may serve as one route of transmission. J Infect Dis 1993;168:222–6.
11. Globocan 2002, IARC, Cancer Mondial. Available from: http://www-dep.iarc.fr/. Accessed May 27, 2006.
12. República de Chile. Ministerio de Salud. Departamento de Estadísticas. Bases de datos de mortalidad, 1985-2002. Santiago, Chile.
13. República de Chile. Ministerio de Salud de Chile. Departamento de Epidemiología. Encuesta Nacional de Salud 2003. Available from: http://epi.minsal.cl/epi/html/invest/ENS/ENS.htm. Accessed May 27, 2006.
14. Kish L. A procedure for objective respondent selection within the household. J Am Stat Assoc 1949;44:380–7.
15. Harris PR, Godoy A, Arenillas S, et al. CagA antibodies as a marker of virulence in Chilean patients with *Helicobacter pylori* infection. J Pediatr Gastroenterol Nutr 2003;37:596–602.
16. Harris P, Perez-Perez G, Zylberberg A, et al. Relevance of adjusted cut-off values in commercial serological immunoassays for *Helicobacter pylori* infection in children. Dig Dis Sci 2005;50:2103–9.
17. Wolter KM. Introduction to variance estimation. New York: Springer-Verlag; 1985.

18. Doll R, Cook P. Summarizing indices for comparison of cancer incidence data. Int J Cancer 1967;2:269–79.
19. República de Chile. Instituto Nacional de Estadísticas (INE). Available from: http://www.ine.cl/canales/chile_estadistico/demografia_y_vitales/proyecciones/MenPrincOK.xls. Accessed May 27, 2006.
20. Besag J, York J, Mollié A. Bayesian image restoration with two applications in spatial statistics. Ann Inst Stat Math 1991;43:1–20.
21. Spiegelhalter D, Thomas A, Best N, et al. WinBUGS version 1.4 user manual. Available from: http://www.mrc-bsu.cam.ac.uk/. Accessed May 27, 2006.
22. Smith BJ. The BOA package. Available from http://www.public-health.uiowa.edu/boa/. Accessed May 27, 2006.
23. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit (with discussion). J R Stat Soc [Ser B] 2002;64:583–640.
24. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702–6.
25. República de Chile. Ministerio de Planificación Nacional. Encuesta CASEN. Available from: http://www.mideplan.cl/casen/form_casen.html. Accessed March 10, 2006.
26. Armijo R. Ecology of stomach cancer in Chile. Natl Cancer Inst Monogr 1982;62:141–3.
27. Torres J, Lopez L, Lazcano E, et al. Trends in *Helicobacter pylori* infection and gastric cancer in Mexico. Cancer Epidemiol Biomarkers Prev 2005;14:1874–7.
28. Camargo C, Yepez C, Ceron C, et al. Age at acquisition of *Helicobacter pylori* infection: comparison of two areas with contrasting risk of gastric cancer. Helicobacter 2004;9:262–70.
29. República de Chile. Ministerio de Salud. Departamento de Epidemiología.
30. Palli D, Cipriani F, Decarli A, et al. Reproductive history and gastric cancer among post-menopausal women. Int J Cancer 1994;56:812–5.
31. Malaty HM, Tanaka E, Kumagai T, et al. Seroepidemiology of *Helicobacter pylori* and hepatitis A virus and the mode of transmission of infection: a 9-year cohort study in rural Japan. Clin Infect Dis 2003;37:1067–72.
32. Yang YJ, Wang SM, Chen CT, et al. Lack of evidence for fecal-oral transmission of *Helicobacter pylori* infection in Taiwanese. J Formos Med Assoc 2003;102:375–8.
33. Soto R, Torche A. Spatial inequality, migration and economic growth in Chile. Instituto de Economía, Pontificia Universidad Católica de Chile. Cuad Econ 2004;41:401–24.
34. Castillo B, Mardones G. [Medical certification in the health services of Chile]. Rev Med Chil 1986;114:693–700.
35. Cutler AF, Havstad S, Ma CK, Blaser MJ, Perez-Perez GI, Schubert TT. Accuracy of invasive and noninvasive tests to diagnose *Helicobacter pylori* infection. Gastroenterology 1995;109:136–41.
36. el-Zimaity HM, al-Assi MT, Genta RM, Graham DY. Confirmation of successful therapy of *Helicobacter pylori* infection: number and site of biopsies or a rapid urease test. Am J Gastroenterol 1995;90:1962–4.
37. Laine L, Chun D, Stein C, El-Beblawi I, Sharma V, Chandrasoma P. The influence of size or number of biopsies on rapid urease test results: a prospective evaluation. Gastrointest Endosc 1996;43:49–53.
38. Yousfi MM, El-Zimaity HM, Cole RA, Genta RM, Graham DY. Detection of *Helicobacter pylori* by rapid urease tests: is biopsy size a critical variable? Gastrointest Endosc 1996;43:222–4.
39. Israel DA, Peek RM, Jr. The role of persistence in *Helicobacter pylori* pathogenesis. Curr Opin Gastroenterol 2006;22:3–7.

Encuesta Calidad de Vida 2000. Available from: http://epi.minsal.cl/epi/html/sdesalud/cdevid/finalnacional.pdf. Accessed July 06, 2006.